Impact BioMedical, INC. Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest
Impact BioMedical, INC. (IBO) reported Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest of -$36.00 thousand for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-10.
Discontinued › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity · last filed 2024-05-10
- Impact BioMedical, INC. income (loss) from continuing operations, net of tax, attributable to noncontrolling interest for the quarter ending 2024-03-31 was -$36.00K.
- Impact BioMedical, INC. income (loss) from continuing operations, net of tax, attributable to noncontrolling interest for the quarter ending 2023-12-31 was -$26.00K.
- Impact BioMedical, INC. income (loss) from continuing operations, net of tax, attributable to noncontrolling interest for the quarter ending 2023-09-30 was -$15.00K.
- Impact BioMedical, INC. income (loss) from continuing operations, net of tax, attributable to noncontrolling interest for the quarter ending 2023-06-30 was -$19.00K.
- Impact BioMedical, INC. income (loss) from continuing operations, net of tax, attributable to noncontrolling interest for fiscal 2023 was -$71.00K.
- Impact BioMedical, INC. income (loss) from continuing operations, net of tax, attributable to noncontrolling interest for fiscal 2022 was -$204.00K.
| Period end | Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest 3 month | Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest 6 month | Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest 9 month | Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2024-03-31 | -$36.00K 10-Q · filed 2024-05-10 | -$62.00K derived: sum of 2 quarters · filed 2024-05-10 | -$77.00K derived: sum of 3 quarters · filed 2024-05-10 | -$96.00K derived: sum of 4 quarters · filed 2024-05-10 |
| 2023-12-31 | -$26.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | -$41.00K derived: sum of 2 quarters · filed 2024-02-20 | -$60.00K derived: sum of 3 quarters · filed 2024-02-20 | -$71.00K 10-K · filed 2024-02-20 |
| 2023-09-30 | -$15.00K 10-Q · filed 2023-11-13 | -$34.00K derived: sum of 2 quarters · filed 2023-11-13 | -$45.00K 10-Q · filed 2023-11-13 | -$230.00K derived: sum of 4 quarters · filed 2024-05-10 |
| 2023-06-30 | -$19.00K 10-Q · filed 2023-10-05 | -$30.00K 10-Q · filed 2023-10-05 | -$215.00K derived: sum of 3 quarters · filed 2024-05-10 | -$282.00K derived: sum of 4 quarters · filed 2024-05-10 |
| 2023-03-31 | -$192.00K 10-Q · filed 2024-05-10 | -$196.00K derived: sum of 2 quarters · filed 2024-05-10 | -$263.00K derived: sum of 3 quarters · filed 2024-05-10 | -$330.00K derived: sum of 4 quarters · filed 2024-05-10 |
| 2022-12-31 | -$4.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | -$71.00K derived: sum of 2 quarters · filed 2024-02-20 | -$138.00K derived: sum of 3 quarters · filed 2024-02-20 | -$204.00K 10-K · filed 2024-02-20 |
| 2022-09-30 | -$67.00K 10-Q · filed 2023-11-13 | -$134.00K derived: sum of 2 quarters · filed 2023-11-13 | -$200.00K 10-Q · filed 2023-11-13 | |
| 2022-06-30 | -$67.00K 10-Q · filed 2023-10-05 | -$133.00K 10-Q · filed 2023-10-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |